7th Annual Addiction Research Symposium

This activity has been approved for AMA PRA Category 6 Credit™

Showcasing the latest evidence-based practices, treatment models and cutting-edge research, this event bridges the gap between practice and research to improve the care of those suffering from substance use disorders. Leading experts in the field of Addiction Medicine from across the country will enlighten the audience about current and future treatment possibilities being explored by researchers today.

Who should attend?

This event is appropriate for those who work in the field of Addiction Medicine, including psychiatrists, addiction medicine physicians, medical residents and students, medical researchers, nurse practitioners, physician assistants, and medical educators. Additionally, those who work with patients with addiction, such as psychologists, behavioral health therapists, and addiction therapists, will find value in attending (check with your licensing board for eligibility of credits).

Agenda - Click here to view full agenda

• 7:30 AM: Registration and continental breakfast
• 8:30 AM - 4:30 PM: 7th Annual Addiction Research Symposium - includes a full lunch with snacks

Click here for exclusive discounted overnight accommodations.

Presentations

Addressing Substance Use Disorder through Penn State Project ECHO: Opportunities and Next Steps - Presented by Jennifer L. Kraschnewski, MD, MPH - Professor of Medicine and Public Health Sciences Vice Chair of Clinical Research, Department of Medicine Director at Penn State Clinical and Translational Science Institute

Exciting New Findings with Transcranial Magnetic Stimulation (TMS) for Treating the Addictions - Presented by Mark George, MD - Director Magnetic Brain Stimulation Laboratory at Medical University of South Carolina

Lessons Learned from a Global COVID-19 Mixed Methods Survey from the Early Pandemic Days - Presented by Rob Lennon, MD, JD, FAAFP - Associate Professor and Director of Resident Scholarly Activity, Department of Family and Community Medicine at Penn State Milton S. Hershey Medical Center

The Neuropsychopharmacology of Psychedelic Drugs - Presented by Frederick Barrett, PhD. - Associate Director, Center of Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine

Alcoholism and its Treatment with Medications and Nutrition - Presented by John Umhau, MD, MPH, CPE – Owner of Alcohol Recovery Medicine

Addressing the Opioid Crisis and Patients Health Outcomes by Maximizing Behavioral Treatment in Chronic Non-Cancer Pain - Presented by Aleksandra Zgierska, MD, PhD, DFASM - Professor and Vice Chair of Research, Penn State College of Medicine Department of Family and Community Medicine at Penn State College of Medicine, Department of Family and Community Medicine

Please email Julie Flannery at Jflannery@caron.org or call 610-299-8001 with any questions about the event.

AMA Credit Designation Statement:

The American Society of Addiction Medicine designates this blended – other (live and on-demand) activity for a maximum of 6 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Addiction Medicine (ASAM) and the Caron Foundation. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CME Committee Reviewer

Cara Poland, MD, Med, DFASAM – No relevant financial disclosures

Presenters

Jennifer L. Kraschnewski, MD, MPH - No relevant financial disclosures

Mark George, MD – Dose disclose

• Babystrong (infant taVNS): Patent co-holder
• Brainsway (TMS): Consultant (unpaid), Research Grant, donated equipment for research trials
• Magnus Medical: Scientific Advisor (unpaid)
• Magstim: Consultant (unpaid) Donated equipment for research trials
• Mecta (ECT): Consultant (unpaid), Research Grant, donated equipment for research grant
• Microtransponder: DSMB member
• Neuronetics (TMS): Consultant (unpaid), Research Grant, Donated Equipment for research
• NeoSync (TMS): Consultant (unpaid), DSMB member
• Neuralief (vns, trigeminal): Scientific Advisory Board, Research Grant
• Sooma: Scientific Advisory Board

Rob Lennon, MD, JD, FAAFP - No relevant financial disclosures

Frederick Barrett, PhD - Does disclose

• WavePaths, Ltd develops music-listening interventions for psychiatric and psychedelic therapies. I receive stock options as a member of the scientific advisor board

John UmHau, MD, MPH, CPE - No relevant financial disclosures

Katie Lain Goyatton - No relevant financial disclosures

Aleksandra Zgierska, MD, PhD, DFASM - No relevant financial disclosures

Planning Committee

Erin Deneke, PhD - No relevant financial disclosures

Julie Flannery - No relevant financial disclosures

Joseph M. Garbely, DO, DFASAM, FAPA - No relevant financial disclosures

Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. These policies include mitigating all relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CE Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.